CGCesar Garzón-Pérez

Cesar Garzón-Pérez

*This is an algorithmically generated author record based on publicly available information.

Cesar Garzón-Pérez has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of a Bacterial Consortium Probiotic Derived from Tropical Calves on the Growth rate, Incidence of Diarrhea, Immune response, and Fecal Microbiota of Holstein Calves

    by Ioana Vicente-Colin, César Garzón-Pérez, Laura González-Dávalos, Bricia Plata-Anaya, María Daniela Frade-Pérez, Reyna M.A. De la Rosa-Romero, Ofelia Mora-Izaguirre

    Calf survival is a relevant issue in animal health and production, since newborns do not have robust immune protection, and the first 30 days of life are critical. Infectious diseases, especially diarrhea, are the main cause of mortality. The immune response is strongly associated with the composition and metabolism of intestinal microbes. The bacterial consortium A1D42 obtained from the rumen of tropical calves has been shown to have excellent probiotic characteristics. Our aim was to evaluate the impact of probiotic administration on key parameters for the survival of Holstein calves. One group of newborns was treated with a Bacterial Consortium Probiotic (BCP) for 30 days and another was considered a control group. Calves that received A1D42 had greater weight gain, and a lower diarrhea frequency compared to the control. They also presented an increase in the concentration of IgG, as well as an increase in the bacterial phylum Bacteroidetes. The administration of Bacterial Consortium Probiotic derived from the same species improves the health parameters of calves and could reduce their mortality.

  • Open Access

    ¿Es posible usar probióticos para prevenir o tratar la obesidad en perros?

    by María Frade-Pérez, Laura González-Dávalos, Cesar Garzón-Pérez, Enrique Flores-Gasca, Ofelia Mora-Izaguirre

    La obesidad canina es un trastorno metabólico complejo y multifactorial que ha aumentado de forma alarmante en todo el mundo, lo que afecta tanto la salud animal como la salud pública. Más allá de la sobrealimentación y la falta de ejercicio, las investigaciones actuales destacan a la microbiota intestinal como un regulador clave del equilibrio metabólico. Las alteraciones en su composición (como el incremento en la relación Firmicutes/Bacteroidetes, y la pérdida de diversidad microbiana) perturban la absorción de nutrientes, el metabolismo de lípidos y la regulación inmunológica, esto genera un entorno proinflamatorio que favorece la acumulación de grasa. Los probióticos, definidos como microorganismos vivos que promueven la salud al administrarse en cantidades adecuadas, muestran potencial para restaurar el equilibrio intestinal y mejorar el metabolismo del hospedero. Su mecanismo de acción implica reforzar la barrera intestinal, modular la respuesta inmunológica y producir ácidos grasos de cadena corta que regulan el uso energético. Sin embargo, la mayoría de los probióticos comerciales para perros derivan de cepas humanas, no diseñadas específicamente para trastornos metabólicos. Evidencias recientes sugieren que cepas de Lactobacillus, Bifidobacterium y Enterococcus de origen canino pueden reducir la adiposidad y mejorar la salud metabólica. El desarrollo de probióticos específicos para perros podría integrarse a estrategias dietéticas y conductuales sostenibles, dentro del marco “Una Salud” que vincula el bienestar animal y humano. https://doi.org/10.21929/abanicomicrobiano/2025.4 2025-04 https://www.youtube.com/watch?v=OfjG63UUW2s Canine obesity is a complex metabolic disorder that has become increasingly common worldwide, affecting not only animal health but also public health and welfare. Beyond excessive feeding and limited exercise, current research highlights the gut microbiota as a central regulator of metabolic balance. Alterations in its composition (such as an increased Firmicutes/Bacteroidetes ratio, and loss of microbial diversity) disrupt nutrient absorption, lipid metabolism, and immune regulation, creating a pro-inflammatory environment that favors fat accumulation. Probiotics, defined as live microorganisms that promote health when administered in sufficient quantities, have shown potential to restore intestinal balance and improve host metabolism. They act by strengthening the intestinal barrier, modulating immunity, and producing short-chain fatty acids that regulate energy use. However, most commercial probiotics for dogs are adapted from human strains and not specifically developed for metabolic disorders. Emerging evidence suggests that canine-derived strains of Lactobacillus, Bifidobacterium, and Enterococcus may help reduce adiposity and improve metabolic health. Designing next-generation, species-specific probiotics could complement dietary and behavioral interventions, offering a sustainable, microbiota-based strategy to prevent and manage obesity in dogs within the broader “One Health” perspective linking animal and human well-being. https://doi.org/10.21929/abanicomicrobiano/2025.4 2025-04 https://www.youtube.com/watch?v=OfjG63UUW2s